Fennec Pharmaceuticals (FENC) to Release Earnings on Thursday

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Fennec Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.26). The company had revenue of $7.26 million for the quarter, compared to the consensus estimate of $13.67 million. Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 53.38%. During the same quarter last year, the business posted ($0.21) earnings per share. On average, analysts expect Fennec Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Fennec Pharmaceuticals Stock Down 0.9 %

NASDAQ:FENC traded down $0.04 on Friday, hitting $4.32. The stock had a trading volume of 41,220 shares, compared to its average volume of 112,488. Fennec Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $11.92. The firm's fifty day simple moving average is $4.97 and its two-hundred day simple moving average is $6.35. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.75 and a current ratio of 8.02. The stock has a market cap of $118.46 million, a P/E ratio of 109.00 and a beta of 0.25.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Craig Hallum dropped their price target on Fennec Pharmaceuticals from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Wednesday, August 14th. Wedbush reissued an "outperform" rating and issued a $14.00 price target (down from $16.00) on shares of Fennec Pharmaceuticals in a report on Tuesday, August 13th. Finally, HC Wainwright decreased their price objective on shares of Fennec Pharmaceuticals from $15.00 to $13.00 and set a "buy" rating for the company in a report on Thursday, August 22nd.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.